Back to Agenda
FDA Update on Prescription Drug Promotion
Session Chair(s)
John Kamp
Washington Counsel
Coalition For Healthcare Communication (CHC), United States
FDA marketing officials from the CDER Office of Prescription Drug Promotion and other related centers will outline the latest major enforcement actions and regulatory guidance and explain major priorities in enforcement actions and area of enforcement concern. Participants can expect a review of the structure and priorities of the marketing enforcement centers, including review of warning letters and current guidances.
Invitations to FDA Marketing Executives are currently pending.
Learning Objective : Describe the latest enforcement priorities and warning letters from FDA OPDP and other enforcement centers that focus on marketing matters.
Speaker(s)
OPDP Enforcement and Guidance Updates
Thomas W. Abrams, MBA, RPh
Former FDA, United States
Retired, Director, Office of Prescription Drug Promotion, OMP, CDER
Social Science Research
Helen W. Sullivan, PhD, MPH
FDA, United States
Social Science Analyst, OPDP, OMP, CDER
Have an account?